2023
Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor J, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal M, Marianayagam N, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera S, Omay S, Mishra-Gorur K, McGuone D, Morales-Valero S, Fulbright R, Gunel M, Erson-Omay E, Moliterno J. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. Journal Of Neurosurgery 2023, 139: 1648-1656. PMID: 37243548, DOI: 10.3171/2023.4.jns222929.Peer-Reviewed Original ResearchConceptsSubtotal resectionSupratentorial tumorsElevated Ki-67High-risk featuresProgression-free survivalChromosome 1p deletionInfratentorial counterpartsInfratentorial tumorsPostoperative managementSomatic driver mutationsCerebral convexityGrade IIInfratentorial meningiomasKi-67Posterior fossaLoss of heterozygosityMeningiomasResectionTumorsWhole-exome sequencing dataDriver mutationsHigh gradeSignificant differencesExome sequencing dataSporadic meningiomasSurgical strategies for intracranial meningioma in the molecular era
Dincer A, Morales-Valero S, Robert S, Tabor J, O’Brien J, Yalcin K, Fulbright R, Erson-Omay Z, Dunn I, Moliterno J. Surgical strategies for intracranial meningioma in the molecular era. Journal Of Neuro-Oncology 2023, 162: 253-265. PMID: 37010677, PMCID: PMC10167142, DOI: 10.1007/s11060-023-04272-z.Peer-Reviewed Original ResearchConceptsExtent of resectionGrade 1 tumorsInfluence of surgeryTreatment of choiceHigh recurrence rateBiology of meningiomasIntroductionSurgical resectionSymptomatic recurrenceDisease recurrenceDefinitive managementRecurrence rateSurgical strategyWHO gradeIntracranial meningiomasClinical predictive powerMalignant transformationGrading scaleNatural historyMeningiomasUnexpected recurrenceRecurrence
2022
EPCO-40. INFRATENTORIAL NF2 MUTANT SPORADIC MENINGIOMAS DIFFER FROM THOSE IN SUPRATENTORIAL LOCATIONS AND ARE MORE BENIGN
Vasandani S, Vetsa S, Jalal M, Yalcin K, Marianayagam N, Nadar A, Jin L, Fulbright R, Erson-Omay E, Günel M, Moliterno J. EPCO-40. INFRATENTORIAL NF2 MUTANT SPORADIC MENINGIOMAS DIFFER FROM THOSE IN SUPRATENTORIAL LOCATIONS AND ARE MORE BENIGN. Neuro-Oncology 2022, 24: vii125-vii125. DOI: 10.1093/neuonc/noac209.474.Peer-Reviewed Original ResearchSupratentorial locationWhole-exome sequencing dataHigh-risk clinical featuresLonger progression-free survivalProgression-free survivalExtent of resectionShorter overall survivalDifferent intracranial locationsChromosome 1p deletionOverall survivalClinical featuresInfratentorial tumorsAggressive featuresClinical manifestationsClinical behaviorKi-67Intracranial locationMeningiomasTumorsUnstable tumorsNF2 lossResectionGenomic profilesPatientsExome sequencing data
2021
NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS
Jin L, Youngblood M, Gupte T, Vetsa S, Nadar A, Barak T, Yalcin K, Aguilera S, Mishra-Gorur K, Blondin N, Omay S, Pointdujour-Lim R, Judson B, Alperovich M, Aboian M, McGuone D, Gunel M, Erson-Omay Z, Fulbright R, Moliterno J. NIMG-64. TYPE OF BONY INVOLVEMENT PREDICTS GENOMIC SUBGROUP IN SPHENOID WING MENINGIOMAS. Neuro-Oncology 2021, 23: vi144-vi144. PMCID: PMC8598770, DOI: 10.1093/neuonc/noab196.562.Peer-Reviewed Original ResearchSphenoid wing meningiomaSpheno-orbital meningiomasBony involvementTRAF7 mutationsTumor invasionGenomic subgroupsPre-operative clinical featuresYale-New Haven HospitalAdditional clinical variablesSubset of tumorsPre-operative predictionLogistic regression modelsWhole-exome sequencingClinical featuresClinical variablesGrade IIPredictive logistic regression modelRecurrence patternsMolecular subtypesClinical implicationsExome sequencingHyperostosisMeningiomasTumorsGenomic drivers